To print: Select File and then Print from your browser's menu

Title: FDA Approves SPOT-Light Test for Patients With Breast Cancer

"FDA Approves SPOT-Light Test for Patients With Breast Cancer"

ROCKVILLE, Md -- July 8, 2008 -- The US Food and Drug Administration (FDA) has approved a novel genetic test, SPOT-Light, for determining whether patients with breast cancer are good candidates for treatment with trastuzumab (Herceptin). "When used with other clinical information and laboratory tests, this test can provide healthcare professionals with additional insight on treatment decisions for patients with breast cancer," said Daniel Schultz, MD, FDA Center for Devices and Radiological Health, Rockville, Maryland. The FDA based its approval of the SPOT-Light test on a study using tumour samples from patients with breast cancer in the United States and Finland. These studies confirmed that the test was effective in determining how many HER2 genes were in these patients. SOURCE: US Food and Drug Administration

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.